论文部分内容阅读
~(201)TL心肌灌注显象在1973年就已介绍过了,对局部缺血性心脏病人的评价中已成为常规方法,但~(201)Tl不是一种理想的放射性心肌显象药物,因为其能量低(80Kev)、半衰期长及在运用后迅速重分布。~(99m)Tc标记的六个化合物如Tc-99m-六个2-甲氧基异丁基异腈(HEXAMIBI)就是一种新的心肌显象剂,它在心肌中的积聚与局部血流成比例,没有明显的重分布,且在肝和肺中的活性在注射后最初1-2小时迅速下降。100例以上病人使用本化合物研究的
Myocardial perfusion imaging of ~ (201) TL has been introduced in 1973, and it has become a routine method in the evaluation of ischemic heart disease. However, ~ (201) Tl is not an ideal drug for radiation myocardial imaging. Because of its low energy (80 Kev), long half-life and rapid redistribution after use. Six compounds labeled with ~ (99m) Tc, such as Tc-99m-HEXAMIBI, are new myocardial imaging agents whose accumulation in the myocardium is proportional to the local blood flow , With no apparent redistribution and a rapid decrease in liver and lung activity for the first 1-2 hours after injection. More than 100 patients studied using this compound